| 期刊簡介 | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LetPub Score 5.2
51 ratings
Rate
Reputation 6.3 Influence 3.9 Speed 7.0 | ||||||||||||||||||||||||||
| 期刊簡稱 | EXP CLIN PSYCHOPHARM | ||||||||||||||||||||||||||
| ISSN | 1064-1297 | ||||||||||||||||||||||||||
| E-ISSN | 1936-2293 | ||||||||||||||||||||||||||
| h-index | 82 | ||||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||||
| 自引率 (2023-2024) | 8.30%自引率趨勢 | ||||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||||
| 官方網站 | http://www.apa.org/pubs/journals/pha/index.aspx | ||||||||||||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/PHA | ||||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||||
| 出版商 | American Psychological Association Inc. | ||||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||||
| 出版國/地區 | UNITED STATES | ||||||||||||||||||||||||||
| 發行頻率 | 四半期刊行 | ||||||||||||||||||||||||||
| 創刊年 | 1993 | ||||||||||||||||||||||||||
| 每年文章數 | 64每年文章數趨勢 | ||||||||||||||||||||||||||
| 黃金OA百分比 | 18.10% | ||||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q2
| ||||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded Social Science Citation Index | ||||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1064-1297%5BISSN%5D | ||||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||||
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY] 的評論 | 撰寫評論 |
| 作者: SK 領域: 審稿時間: 0.0 month(s) 結果: 拒稿 撰寫評論 |
2024-06-15 03:10:54 評論於 Review process was exceptionally quick. Reviews were positive, so cannot speak to the process if reviewers are hostile etc, but just in terms of rapidity of review, I strongly recommend ECP. But this has to be balanced against it's v modest impact factor (if you care about that sort of thing).  (0) 讚！ | SK  |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 20:02:35 評論於 The discussion section is the core part of a SCI paper, as it can reflect the breadth and depth of the author's research. Therefore, there is no specific word limit for this section. Different articles and authors may have varying lengths for their discussion sections, ranging from a few thousand words to tens of thousands of words (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 13:12:21 評論於 The discussion section is the core part of an SCI paper because it can reflect the breadth and depth of the author's research. Therefore, there is no limit to the number of words in this section. Depending on the article and the author, the length of the discussion section varies, ranging from a few thousand words to tens of thousands of words (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 上清雨真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-28 10:01:21 評論於 How many words should be used in a discussion on average? (0) 讚！ | 上清雨真 |
| 作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-28 09:02:00 評論於 Does the lengthy discussion reveal the author's reflection on the topic? Does it leave a good impression on the reviewers? (0) 讚！ | Oswald Edie |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
